| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Angiotensin AT2 receptor (AT2R) and AT1 receptor. Angiotensin III has approximately 30-fold higher affinity for AT2R (IC₅0 = 0.648 nM) compared to AT1R (IC₅0 = 21.1 nM) in HEK293 cells. It also binds to AT1R with lower affinity. It is the preferred agonist for renal AT2 receptors.
|
|---|---|
| ln Vitro |
In HEK293 cells expressing rat or human receptors, Angiotensin III shows high potency at AT2R (IC₅0 = 0.648 nM) and moderate activity at AT1R (IC₅0 = 21.1 nM). It stimulates AT2R-mediated signaling pathways including protein phosphatase 2A (PP2A) activation and natriuresis. It induces aldosterone synthesis comparable to angiotensin II.
|
| ln Vivo |
Angiotensin III increases urine sodium excretion, fractional sodium excretion, and lithium excretion in vivo, indicating a natriuretic effect mediated by renal AT2 receptors. It has lower vasoconstrictive activity than angiotensin II but induces comparable aldosterone synthesis. It is involved in blood pressure regulation and sodium homeostasis.
|
| Enzyme Assay |
Competitive binding assays using radiolabeled [¹2⁵I]-Sar¹-Ile⁸-angiotensin II and membrane preparations from HEK293 cells expressing human AT1R or AT2R. Membranes are incubated with the radiolabeled ligand and varying concentrations of Angiotensin III at 25degC for 1-2 hours. Bound radioactivity is measured after filtration. IC₅0 values are calculated from competition curves.
|
| Cell Assay |
Cells expressing AT2R (e.g., HEK293-AT2R, certain neuronal cell lines, or PC12W cells) are treated with Angiotensin III (0.1-100 nM). AT2R-mediated responses including sodium excretion studies are performed, or PP2A activity is measured. cGMP accumulation (AT2R signaling) may be quantified by ELISA. For AT1R responses, calcium flux is measured using fluorescent calcium indicators such as Fura-2.
|
| Animal Protocol |
In rodents, Angiotensin III is administered intravenously or via intrarenal artery infusion (e.g., doses ranging from 1-100 nmol/kg). Blood pressure is monitored via arterial catheter. Urine is collected for measurement of sodium, potassium, and lithium excretion. Plasma aldosterone levels may be measured by radioimmunoassay or ELISA. Renal blood flow is measured by ultrasonic flow probes.
|
| ADME/Pharmacokinetics |
As a heptapeptide (MW ~1045.1 g/mol as TFA salt), Angiotensin III has a short plasma half-life (minutes) due to rapid degradation by aminopeptidases (particularly aminopeptidase A and N) and angiotensin-converting enzyme. It is cleared by the kidneys and metabolized in the blood and tissues. The TFA salt enhances stability and solubility.
|
| Toxicity/Toxicokinetics |
No specific toxicity data reported. As an endogenous peptide, Angiotensin III is generally well-tolerated at research doses. At high doses, the AT1R-mediated effects (vasoconstriction, increased blood pressure) could be observed. Standard safety precautions for handling peptides and trifluoroacetic acid salts apply.
|
| Additional Infomation |
Angiotensin III is also known as [Des-Asp¹]-angiotensin II. It is the primary angiotensin peptide in the brain and kidney and plays a distinct role from angiotensin II in sodium excretion and blood pressure regulation. Not FDA-approved; strictly for research use. It has been studied for potential roles in cognitive function and renal protection.
|
| Molecular Formula |
C48H67F3N12O11
|
|---|---|
| Molecular Weight |
1045.11
|
| Related CAS # |
Angiotensin III, human, mouse;13602-53-4
|
| Appearance |
White to light yellow solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.9568 mL | 4.7842 mL | 9.5684 mL | |
| 5 mM | 0.1914 mL | 0.9568 mL | 1.9137 mL | |
| 10 mM | 0.0957 mL | 0.4784 mL | 0.9568 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
